Patients with sickle cell disease often suffer from painful attacks known as vaso-occlusive crises, during which their sickle-shaped blood cells get stuck in tiny capillaries, depriving tissues of needed oxygen. Blood transfusions can sometimes prevent such attacks, but there are currently no good ways to predict when a vaso-occlusive crisis, which can last for several days, is imminent.
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that preclinical data and initial clinical data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with chemoradiotherapy in non-metastatic rectal cancer was presented at the ASCO 2015 Gastrointestinal Cancers Symposium held January 15-17, 2015.
Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, today announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both studies were presented today at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif.
More efficient medical treatments could be developed thanks to a new method for triggering the rearrangement of chemical particles.
Nanoparticle drugs--tiny containers packed with medicine and with the potential to be shipped straight to tumors--were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall survival rates for cancer patients very much. Scientists at the University of North Carolina at Chapel Hill now think that failure may have less to do with the drugs and tumors than it does the tumor's immediate surroundings.
Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and â-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC).
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society.
Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA™ (TRIal establishing bioequivalence [BE] between Cynviloq™ and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January.
Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, announced today that they have agreed to merge to create a new leading global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.